Regenerating pancreatic beta cells and restoring natural insulin production
With over 420 million Type 2 diabetes patients worldwide, stem cell technology offers a revolutionary breakthrough. Unlike traditional treatments that rely on medication, stem cell therapy can repair damaged pancreatic function and potentially reverse the disease course.
Umbilical cord mesenchymal stem cells (UC-MSCs) are the primary cell type used in clinical applications. These cells can differentiate into insulin-producing beta cells, rebuild insulin secretion function, and improve the pancreatic microenvironment through paracrine signaling.
Back to Therapies Contact UsStem cell therapy addresses the root causes of Type 2 diabetes
Stem cells differentiate into beta cells, rebuilding insulin secretion function while protecting residual beta cells from further damage.
Regulate chronic inflammatory microenvironment, reduce inflammatory factors, and inhibit autoimmune attacks on pancreatic islets.
Simultaneously improve fatty liver, dyslipidemia, and vascular lesions, significantly reducing risk of kidney disease and retinopathy.
UC-MSCs from newborn umbilical cords have minimal immunogenicity with no serious adverse events reported globally.
Landmark studies from PLA General Hospital (301 Hospital) and other institutions
China is the first country to achieve large-scale clinical application of stem cell therapy for Type 2 diabetes
Two dedicated stem cell drugs approved by NMPA for clinical trials, including HF001 gene-modified stem cell injection
CAS team solved three global challenges in islet organoid maturation and vascularization, published in Cell Discovery
Over 200 clinical studies with 5000+ subjects - largest dataset globally
Contact us for personalized consultation on stem cell treatment for diabetes
Consult Now